{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:02:33Z","timestamp":1789614153081,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.breast.2026.104902","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:02:08Z","timestamp":1786518128000},"page":"104902","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Beyond safety: rethinking concomitant radiotherapy and trastuzumab deruxtecan in metastatic breast cancer \u2014 from feasibility to precision practice"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9011-8349","authenticated-orcid":false,"given":"Yueting","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benyuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104902_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2026.104691","article-title":"Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohort","volume":"85","author":"Visani","year":"2026","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.breast.2026.104902_bib2","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S1470-2045(23)00534-X","article-title":"International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: ESTRO-endorsed recommendations","volume":"25","author":"Meattini","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104902_bib3","first-page":"541","article-title":"Stereotactic radiosurgery increases blood-brain barrier permeability in a dose-dependent manner: a dynamic contrast-enhanced MRI study","volume":"137","author":"Wong","year":"2018","journal-title":"J Neuro Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104902_bib4","first-page":"33","article-title":"Concurrent trastuzumab deruxtecan and radiation therapy in HER2-positive and HER2-low metastatic breast cancer","volume":"49","author":"Bouziane","year":"2026","journal-title":"Clin Oncol"},{"issue":"20","key":"10.1016\/j.breast.2026.104902_bib5","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from trastuzumab emtansine","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.breast.2026.104902_bib6","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104902_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110461","article-title":"Risk of radionecrosis in HER2-positive breast cancer with brain metastasis receiving trastuzumab emtansine (T-DM1) and brain stereotactic radiosurgery","volume":"199","author":"Chun","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.breast.2026.104902_bib8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41523-024-00711-w","article-title":"Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases","volume":"10","author":"Khatri","year":"2024","journal-title":"npj Breast Cancer"},{"issue":"suppl 2","key":"10.1016\/j.breast.2026.104902_bib9","first-page":"S1","article-title":"Trastuzumab deruxtecan vs trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer: primary efficacy and safety results from the phase 3 DESTINY-Breast05 trial","volume":"36","author":"Dent","year":"2025","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104902_bib10","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3390\/ph19060833","article-title":"Cardiovascular toxicity of novel HER2-targeted agents and multikinase inhibitors in oncology: from mechanisms to real-world clinical evidence","volume":"19","author":"Abu Suleiman","year":"2026","journal-title":"Pharmaceuticals"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:27:57Z","timestamp":1789612077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626002122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":10,"alternative-id":["S0960977626002122"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104902","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond safety: rethinking concomitant radiotherapy and trastuzumab deruxtecan in metastatic breast cancer \u2014 from feasibility to precision practice","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104902","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104902"}}